Rezvilutamide Outperformed Bicalutamide in Prostate Cancer Study
A recent retrospective study linked rezvilutamide to improved survival outcomes compared to bicalutamide in mHSPC patients.
Updated on Sept. 19, 2026 in Cancer
Between 2021 and 2024, researchers conducted a comparative analysis of rezvilutamide and bicalutamide in patients with high-volume metastatic hormone-sensitive prostate cancer. The study found that rezvilutamide offered superior radiographic progression-free survival outcomes compared to the bicalutamide treatment group.
Why it matters
Real-world clinical data comparing these two treatments for high-volume mHSPC patients had previously been limited. These findings provide additional evidence to support treatment selection for patients battling this form of advanced prostate cancer.
In a study of 50 patients per group, rezvilutamide yielded an 84% PSA50 response and a 50% PSA90 response, compared to 62% and 28% respectively for bicalutamide. Grade 3 or higher adverse events occurred in 26% of the rezvilutamide group versus 24% for the bicalutamide group.
The details
The analysis utilized propensity-score matching to compare patients receiving androgen-deprivation therapy alongside either rezvilutamide or bicalutamide. Researchers observed that rezvilutamide extended the time to castration resistance to 18.6 months and time to PSA progression to 20.1 months, significantly outpacing the 11.4 and 12.9 month durations seen with bicalutamide.
Timeline
The study tracked patient treatments occurring between 2021 and 2024.
The Big Picture
This retrospective study updates clinical figures previously established by standard androgen-deprivation therapy protocols for mHSPC. It provides a comparative benchmark for newer therapeutic agents in a field where real-world efficacy data has historically been sparse.
These findings may influence clinical discussions regarding medication choices and expected progression timelines for patients with metastatic prostate cancer. Patients should consult with their oncologists to determine if these comparative results are relevant to their specific medical history.
The takeaway
While rezvilutamide showed superior progression-free survival metrics in this retrospective cohort, the occurrence of adverse events remained comparable between the two groups. Future clinical trials and long-term data will be essential to validate these findings for broader medical application.
Further reading
For additional context on advancements in oncological research, visit the Cancer section.
Source note: This article includes information reported by Nature.
